Cho J H, Balasubramanyam M, Chernaya G, Gardner J P, Aviv A, Reeves J P, Dargis P G, Christian E P
Hypertension Research Program, University of Medicine and Dentistry-New Jersey Medical School, 185 South Orange Avenue, Newark, NJ 07103, USA.
Biochem J. 1997 Jun 15;324 ( Pt 3)(Pt 3):971-80. doi: 10.1042/bj3240971.
Inhibitors of mitochondrial oxidative metabolism have been proposed to interfere with Ca2+ influx mediated by store-operated channels (SOC), secondary to their effects on ATP production. We assessed SOC activity by 45Ca2+ influx and fluorimetric measurements of free Ca2+ or Mn2+ quench in thapsigargin-treated Chinese hamster ovary cells and Jurkat T-cells, and additionally by electrophysiological measurements of the Ca2+-release-activated Ca2+ current (Icrac) in Jurkat T-cells. Various mitochondrial antagonists were confirmed to inhibit SOC. However, the following evidence supported the proposal that oligomycin, in particular, exerts an inhibitory effect on SOC in addition to its known actions on mitochondria and Na+-pump activity: (i) the concentrations of oligomycin required to inhibit SOC-mediated Ca2+ influx or Icrac (half-inhibitory concentration approximately 2 microM) were nearly 50-fold higher than the concentrations that blocked mitochondrial ATP production; (ii) the rank order of potency of oligomycins A, B and C for decreasing SOC-mediated Ca2+ influx or Icrac differed from that known for inhibition of mitochondrial function; (iii) oligomycin blocked Icrac under voltage clamp and with intracellular Na+ and K+ concentrations fixed by dialysis from the patch pipette, arguing that the effect was not secondary to membrane polarization or pump activity; and (iv) fixing the cytosolic ATP concentration by dialysis from the patch pipette attenuated rotenone- but not oligomycin-mediated inhibition of Icrac. Oligomycin also blocked volume-activated Cl- currents, a profile common to some other known blockers of SOC that are not known mitochondrial inhibitors. These findings raise the possibility that oligomycin interacts directly with SOC, and thus may extend the known pharmacological profile for this type of Ca2+-influx pathway.
线粒体氧化代谢抑制剂被认为会干扰由储存-操作性通道(SOC)介导的Ca2+内流,这是其对ATP生成产生影响的继发效应。我们通过45Ca2+内流以及荧光法测量毒胡萝卜素处理的中国仓鼠卵巢细胞和Jurkat T细胞中的游离Ca2+或Mn2+淬灭来评估SOC活性,此外还通过电生理测量Jurkat T细胞中的Ca2+释放激活的Ca2+电流(Icrac)。各种线粒体拮抗剂均被证实可抑制SOC。然而,以下证据支持这样的观点,即特别是寡霉素,除了其对线粒体和Na+泵活性的已知作用外,还对SOC发挥抑制作用:(i)抑制SOC介导的Ca2+内流或Icrac所需的寡霉素浓度(半数抑制浓度约为2 microM)比阻断线粒体ATP生成的浓度高近50倍;(ii)寡霉素A、B和C降低SOC介导的Ca2+内流或Icrac的效力排序与已知的抑制线粒体功能的排序不同;(iii)在电压钳制下且通过膜片吸管透析固定细胞内Na+和K+浓度时,寡霉素阻断Icrac,这表明该效应并非继发于膜极化或泵活性;(iv)通过膜片吸管透析固定胞质ATP浓度可减弱鱼藤酮介导但不能减弱寡霉素介导的对Icrac的抑制。寡霉素还阻断容积激活的Cl-电流,这是一些其他已知的SOC阻断剂(并非线粒体抑制剂)共有的特征。这些发现增加了寡霉素直接与SOC相互作用的可能性,因此可能扩展这种类型的Ca2+内流途径的已知药理学特征。